1,3,5-triaza-7-phosphaadamantane has been researched along with Acute Confusional Senile Dementia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atrián-Blasco, E; Cerrada, E; Faller, P; Hureau, C; Laguna, M | 1 |
| Atrián-Blasco, E; Cerrada, E; Conte-Daban, A; Faller, P; Hureau, C; Laguna, M; Testemale, D | 1 |
2 other study(ies) available for 1,3,5-triaza-7-phosphaadamantane and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Role of PTA in the prevention of Cu(amyloid-β) induced ROS formation and amyloid-β oligomerisation in the presence of Zn.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Copper; Humans; Ligands; Organophosphorus Compounds; Protein Multimerization; Reactive Oxygen Species; Zinc | 2019 |
Copper(I) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Copper; Humans; Organophosphorus Compounds; Oxidation-Reduction; Reactive Oxygen Species | 2015 |